Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
212 Results Found
AHA 340B Advocacy Alliance Bulletin - March 12, 2026
Urge your Representative to sign Hill Letter on 340B Rebate Model.
AHA 340B Advocacy Alliance - March 3, 2026
The AHA today urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect by April 1.
AHA Letter to HRSA Regarding a New Concerning Development with the 340B Program
AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.
AHA 340B Advocacy Alliance Bulletin - February 25, 2026
The Health Resources and Services Administration today said it will extend the deadline to April 20 to receive comments.
Use Revised AHA Model Letter to Submit Comments on 340B Rebate Model RFI by New April 20 Deadline
HRSA has extended comment deadline and suggested a significantly expanded scope of rebate program.
HHS Releases RFI on New 340B Rebate Model
The Department of Health and Human Services today issued a request for information on a new 340B rebate model program.
Action Alert on 340B Rebate Model RFI
It is critical that HRSA hear from as many 340B hospitals as possible about the costs and administrative burdens a rebate model program would impose.
AHA Comments on CMS Proposed GLOBE Model
While the AHA broadly supports the Administration’s objectives as described in the proposed rule, we believe the GLOBE Model as proposed lacks critical operational details that, if not properly clarified, could create additional burden for hospitals and health systems.
AHA 340 Advocacy Alliance Bulletin - February 23, 2026
Hospitals should submit letters to HRSA by March 19.
Fact Sheet: 340B Drug Pricing Program Contract Pharmacy Arrangements
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for patients in vulnerable communities.